- Report
- August 2018
- 57 Pages
Global
From €9612EUR$10,000USD£8,242GBP
- Report
- July 2018
- 65 Pages
Global
From €9612EUR$10,000USD£8,242GBP
- Drug Pipelines
- July 2018
- 503 Pages
Global
From €21145EUR$22,000USD£18,133GBP
- Drug Pipelines
- July 2018
- 616 Pages
Global
From €21145EUR$22,000USD£18,133GBP
- Report
- October 2022
- 182 Pages
Global
From €1922EUR$2,000USD£1,648GBP
- Report
- July 2022
- 714 Pages
Global
From €2403EUR$2,500USD£2,061GBP
- Report
- April 2022
- 632 Pages
Global
From €2403EUR$2,500USD£2,061GBP
- Report
- July 2022
- 274 Pages
Global
From €5594EUR$5,820USD£4,797GBP
Stelara is a biologic drug used to treat immune disorders such as psoriasis, Crohn's disease, and ulcerative colitis. It is a monoclonal antibody that works by blocking the action of two proteins, interleukin 12 and interleukin 23, which are involved in the body's inflammatory response. Stelara is administered as an injection or infusion, and is typically used in combination with other medications.
Stelara is a relatively new drug, having been approved by the US Food and Drug Administration in 2009. It has become a popular treatment option for immune disorders due to its effectiveness and relatively low side effects.
The Stelara market is highly competitive, with several major pharmaceutical companies offering their own versions of the drug. These include Johnson & Johnson, AbbVie, Merck, and Pfizer. Other companies, such as Amgen and Biogen, are also developing their own versions of the drug. Show Less Read more
